Sequencing of tumors and drugs targeted to mutations found in those cancers are beginning to change how cancer is treated, the Wall Street Journal reports.

The newspaper focuses on Kellie Carey, a lung cancer patient who was given a few months to live back in 2010. But through persistence, Carey persuaded her physicians to genotype her tumor, and they uncovered that she had an ALK gene mutation that could be targeted by Pfizer's Xalkori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Circle Widens

In a Name

Peace of Mind

The Next Step

This Week in Science

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.